Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | GMNN | O75496 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21877811 | 0.87 | LMNA (0.60) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL21877806 | 0.87 | LMNA (0.60) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL21647333 | 0.87 | LMNA (0.60) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL5824225 | 0.85 | MEN1 (0.63) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL1643494 | 0.85 | MEN1 (0.63) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL25099265 | 0.84 | LMNA (0.66) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL12137159 | 0.84 | LMNA (0.66) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL12152164 | 0.84 | LMNA (0.66) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| Bromide SCHEMBL2995962 | 0.83 | LMNA (0.64) | LMNASMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL20530318 | 0.83 | LMNA (0.64) | LMNASMN1; SMN2CYP1A2MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | HEMOSHEAR THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4319746-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Hemoshear Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216848-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Hemoshear Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220142955-A1 | METHODS OF TREATING ORGANIC ACIDEMIAS | Hemoshear Therapeutics, Inc. | 2022-05-12 | — | — | US | disclosed |
| EP-3937922-A1 | METHODS OF TREATING ORGANIC ACIDEMIAS | Hemoshear Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113557014-A | Method for treating organic acidemia | 止血治疗有限公司 | 2021-10-26 | — | — | CN | disclosed |
| WO-2020186216-A1 | METHODS OF TREATING ORGANIC ACIDEMIAS | HEMOSHEAR THERAPEUTICS, LLC (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | MMAB, OTC, ME2 | LMNA 1766/4885SMN1; SMN2 100/4885CYP1A2 2193/4885 |
| US-20220142955-A1 | METHODS OF TREATING ORGANIC ACIDEMIAS | OTC, OAT, PCCA | LMNA 1613/4885SMN1; SMN2 576/4885CYP1A2 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.